SEC Comment Letter 0000000000-24-003343 to Annexon, Inc. (ANNX) (CIK 0001528115) (ANNX)
Annexon, Inc. (ANNX) (CIK 0001528115)
Date: March 28, 2024 · CIK: 0001528115 · Accession: 0000000000-24-003343
AI Filing Summary & Sentiment
File numbers found in text: 333-278246
Letter
United States securities and exchange commission logo March 28, 2024 Douglas Love President and Chief Executive Officer Annexon, Inc. 1400 Sierra Point Parkway, Bldg C, Suite 200 Brisbane, CA 94005 Re:Annexon, Inc. Registration Statement on Form S-3 Filed March 26, 2024 File No. 333-278246 Dear Douglas Love: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Anitha Anne
Show Raw Text
United States securities and exchange commission logo
March 28, 2024
Douglas Love
President and Chief Executive Officer
Annexon, Inc.
1400 Sierra Point Parkway, Bldg C, Suite 200
Brisbane, CA 94005
Re:Annexon, Inc.
Registration Statement on Form S-3
Filed March 26, 2024
File No. 333-278246
Dear Douglas Love:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Anitha Anne